Human Glioma Migration and Infiltration Properties As a Target for Personalized Radiation Medicine

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2018 Nov 23

PMID 30463322

Citations 30

Authors

Michaela Wank

Daniela Schilling

Thomas E Schmid

Bernhard Meyer

Jens Gempt

Melanie Barz

Jurgen Schlegel

Friederike Liesche

Kerstin A Kessel

Benedikt Wiestler

Stefanie Bette

Claus Zimmer

Stephanie E Combs

Affiliations

Soon will be listed here.

Abstract

Gliomas are primary brain tumors that present the majority of malignant adult brain tumors. Gliomas are subdivided into low- and high-grade tumors. Despite extensive research in recent years, the prognosis of malignant glioma patients remains poor. This is caused by naturally highly infiltrative capacities as well as high levels of radio- and chemoresistance. Additionally, it was shown that low linear energy transfer (LET) irradiation enhances migration and invasion of several glioma entities which might counteract today's treatment concepts. However, this finding is discussed controversially. In the era of personalized medicine, this controversial data might be attributed to the patient-specific heterogeneity that ultimately could be used for treatment. Thus, current developments in glioma therapy should be seen in the context of intrinsic and radiation-enhanced migration and invasion. Due to the natural heterogeneity of glioma cells and different radiation responses, a personalized radiation treatment concept is suggested and alternative radiation concepts are discussed.

Citing Articles

Impact of Radiation on Invasion and Migration of Glioma In Vitro and In Vivo.

Santiago Franco M, Raulefs S, Schilling D, Combs S, Schmid T Cancers (Basel). 2024; 16(23).

PMID: 39682088 PMC: 11640451. DOI: 10.3390/cancers16233900.

Advanced image generation for cancer using diffusion models.

Kidder B Biol Methods Protoc. 2024; 9(1):bpae062.

PMID: 39258159 PMC: 11387006. DOI: 10.1093/biomethods/bpae062.

Combination of ionizing radiation and 2-thio-6-azauridine induces cell death in radioresistant triple negative breast cancer cells by downregulating CD151 expression.

Marni R, Malla M, Chakraborty A, Voonna M, Bhattacharyya P, Kgk D Cancer Chemother Pharmacol. 2024; 94(5):685-706.

PMID: 39167147 DOI: 10.1007/s00280-024-04709-w.

Personalized prognosis stratification of newly diagnosed glioblastoma applying a statistical decision tree model.

Conrad K, Lober-Handwerker R, Hazaymeh M, Rohde V, Malinova V J Neurooncol. 2024; 168(3):425-433.

PMID: 38639854 PMC: 11186892. DOI: 10.1007/s11060-024-04683-6.

High-Resolution Microscopic Characterization of Tunneling Nanotubes in Living U87 MG and LN229 Glioblastoma Cells.

Matejka N, Amarlou A, Neubauer J, Rudigkeit S, Reindl J Cells. 2024; 13(5.

PMID: 38474428 PMC: 10931022. DOI: 10.3390/cells13050464.

References

Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M . Long-term survival with glioblastoma multiforme. Brain. 2007; 130(Pt 10):2596-606. DOI: 10.1093/brain/awm204. View

Badiga A, Chetty C, Kesanakurti D, Are D, Gujrati M, Klopfenstein J . MMP-2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PLoS One. 2011; 6(6):e20614. PMC: 3116828. DOI: 10.1371/journal.pone.0020614. View

Peres E, Gerault A, Valable S, Roussel S, Toutain J, Divoux D . Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe. Oncotarget. 2014; 6(4):2101-19. PMC: 4385839. DOI: 10.18632/oncotarget.2937. View

Qiu J, Shi Z, Jiang J . Cyclooxygenase-2 in glioblastoma multiforme. Drug Discov Today. 2016; 22(1):148-156. PMC: 5226867. DOI: 10.1016/j.drudis.2016.09.017. View

Kleihues P, Burger P, Scheithauer B . The new WHO classification of brain tumours. Brain Pathol. 1993; 3(3):255-68. DOI: 10.1111/j.1750-3639.1993.tb00752.x. View

Walker M, Green S, Byar D, ALEXANDER Jr E, Batzdorf U, Brooks W . Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303(23):1323-9. DOI: 10.1056/NEJM198012043032303. View

Graf R, Hildebrandt B, Tilly W, Sreenivasa G, Ullrich R, Felix R . Dose-escalated conformal radiotherapy of glioblastomas -- results of a retrospective comparison applying radiation doses of 60 and 70 Gy. Onkologie. 2005; 28(6-7):325-30. DOI: 10.1159/000085574. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Piroth M, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C . Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison. Radiat Oncol. 2009; 4:57. PMC: 2787527. DOI: 10.1186/1748-717X-4-57. View

10.

Baumann M, Dubois W, Pu A, Freeman J, Suit H . Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation. Int J Radiat Oncol Biol Phys. 1992; 23(4):803-9. DOI: 10.1016/0360-3016(92)90653-y. View

11.

Cordes N, Hansmeier B, Beinke C, Meineke V, van Beuningen D . Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. Br J Cancer. 2003; 89(11):2122-32. PMC: 2376852. DOI: 10.1038/sj.bjc.6601429. View

12.

Jiang J, Qiu J, Li Q, Shi Z . Prostaglandin E2 Signaling: Alternative Target for Glioblastoma?. Trends Cancer. 2017; 3(2):75-78. PMC: 5518646. DOI: 10.1016/j.trecan.2016.12.002. View

13.

Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss D, Sahm F . Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 2018; 136(1):153-166. DOI: 10.1007/s00401-018-1849-4. View

14.

Raychaudhuri B, Vogelbaum M . IL-8 is a mediator of NF-κB induced invasion by gliomas. J Neurooncol. 2010; 101(2):227-35. DOI: 10.1007/s11060-010-0261-2. View

15.

Vilalta M, Rafat M, Graves E . Effects of radiation on metastasis and tumor cell migration. Cell Mol Life Sci. 2016; 73(16):2999-3007. PMC: 4956569. DOI: 10.1007/s00018-016-2210-5. View

16.

Stupp R, Weber D . The role of radio- and chemotherapy in glioblastoma. Onkologie. 2005; 28(6-7):315-7. DOI: 10.1159/000085575. View

17.

Baumert B, Brada M, Bernier J, Kortmann R, Dehing-Oberije C, Collette L . EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm. Radiother Oncol. 2008; 88(2):163-72. DOI: 10.1016/j.radonc.2008.03.025. View

18.

Suit H, Zietman A, Tomkinson K, Ramsay J, Gerweck L, Sedlacek R . Radiation response of xenografts of a human squamous cell carcinoma and a glioblastoma multiforme: a progress report. Int J Radiat Oncol Biol Phys. 1990; 18(2):365-73. DOI: 10.1016/0360-3016(90)90102-p. View

19.

Steinle M, Palme D, Misovic M, Rudner J, Dittmann K, Lukowski R . Ionizing radiation induces migration of glioblastoma cells by activating BK K(+) channels. Radiother Oncol. 2011; 101(1):122-6. DOI: 10.1016/j.radonc.2011.05.069. View

20.

Zhen L, Li J, Zhang M, Yang K . MiR-10b decreases sensitivity of glioblastoma cells to radiation by targeting AKT. J Biol Res (Thessalon). 2016; 23:14. PMC: 4921021. DOI: 10.1186/s40709-016-0051-x. View